Endologix to Present at the Stephens Fall Investment Conference

IRVINE, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Shelley Thunen, Chief Financial Officer, is scheduled to present at the Stephens Fall Investment Conference in New York.

Event: Stephens Fall Investment Conference  
Date: Wednesday, November 13, 2013  
Time: 10:00 a.m. ET / 7:00 a.m. PT

An audio webcast of the Company's presentation at the Stephens Fall Investment Conference will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

CONTACT: COMPANY CONTACT:

Endologix, Inc.
John McDermott, CEO  
Shelley Thunen, CFO  
(949) 595-7200  
www.endologix.com

INVESTOR CONTACTS:

The Ruth Group  
Nick Laudico (646) 536-7030  
Zack Kubow (646) 536-7020

Source: Endologix

News Provided by Acquire Media